In a filing, PTC Therapeutics Inc revealed its CHIEF FINANCIAL OFFICER Gravier Pierre unloaded Company’s shares for reported $77200.0 on Jul 16 ’24. In the deal valued at $34.02 per share,2,269 shares were sold. As a result of this transaction, Gravier Pierre now holds 53,531 shares worth roughly $1.81 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ZELDIS JEROME B sold 20,000 shares, generating $764,800 in total proceeds. Upon selling the shares at $38.24, the Director now owns 14,500 shares.
Before that, Golden Lee Scott sold 175 shares. PTC Therapeutics Inc shares valued at $5,744 were divested by the EVP & CHIEF MEDICAL OFFICER at a price of $32.82 per share. As a result of the transaction, Golden Lee Scott now holds 59,813 shares, worth roughly $2.02 million.
Robert W. Baird initiated its PTC Therapeutics Inc [PTCT] rating to an Outperform in a research note published on September 04, 2024; the price target was $44. Raymond James also remained covering PTCT and has increased its forecast on May 20, 2024 with a “Mkt perform” recommendation from previously “an Underperform” rating. Morgan Stanley revised its rating on December 19, 2023. It rated PTCT as “an Underweight” which previously was an “an Equal-weight”.
Price Performance Review of PTCT
On Monday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock fall -0.65% to $33.77. Over the last five days, the stock has gained 7.48%. PTC Therapeutics Inc shares have risen nearly 22.53% since the year began. Nevertheless, the stocks have fallen -9.68% over the past one year. While a 52-week high of $40.69 was reached on 05/21/24, a 52-week low of $17.53 was recorded on 02/13/24. SMA at 50 days reached $33.07, while 200 days put it at $30.57.
Levels Of Support And Resistance For PTCT Stock
The 24-hour chart illustrates a support level at 33.49, which if violated will result in even more drops to 33.21. On the upside, there is a resistance level at 34.14. A further resistance level may holdings at 34.50. The Relative Strength Index (RSI) on the 14-day chart is 53.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 43.10%. Stochastics %K at 52.10% indicates the stock is a holding.
How much short interest is there in PTC Therapeutics Inc?
A steep rise in short interest was recorded in PTC Therapeutics Inc stocks on 2024-08-30, dropping by -0.11 million shares to a total of 5.63 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-31 was 5.74 million shares. There was a decline of -1.95%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $37 price target.
